You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Details for Patent: 6,080,759


✉ Email this page to a colleague

« Back to Dashboard


Title: Paroxetine hydrochloride form A
Abstract:"Paroxetine hydrochloride (I) anhydrate free of bound propan-2-ol, and various forms thereof, are useful in the treatment of depression and other disorders for which administration of selective serotonin reuptake inhibitors are indicated."
Inventor(s): Ward; Neal (Crowborough, GB), Jacewicz; Victor Witold (Tunbridge Wells, GB)
Assignee: SmithKline Beecham Corporation (Philadelphia, PA)
Filing Date:Sep 02, 1997
Application Number:08/922,062
Claims:1. Paroxetine hydrochloride anhydrate Form A made according to the process which comprises crystallizing a paroxetine hydrochloride in an organic solvent or a mixture of organic solvents to prepare a paroxetine hydrochloride having organic solvent not removable by drying and thereafter displacing the solvent with a displacing agent, wherein paroxetine hydrochloride anhydrate Form A comprises the following characteristics: a melting point of about 123-125.degree. C.; IR bands at about 513, 538, 571, 592, 613, 665, 722, 761, 783, 806, 818, 839, 888, 906, 924, 947, 966, 982, 1006, 1034, 1068, 1091, 1134, 1194, 1221, 1248, 1286, 1340, 1387, 1493, 1513, 1562, 1604, 3402, and 3631 cm.sup.-1 ; a DSC maximum endotherm, measured at 10.degree. C. per minute, of about 126.degree. C. in an open pan and about 121.degree. C. in a closed pan; characteristic X-ray diffractogram peaks at about 6.6, 8.0, 11.2, and 13.1 degrees 2 theta; characteristic solid state .sup.13 C-NMR spectrum peaks at about 154.3, 149.3, 141.6, and 138.5 ppm.

2. Paroxetine hydrochloride anhydrate Form A made according to the process of claim 1 which comprises crystallizing a paroxetine hydrochloride in propan-2-ol, propan-1-ol, ethanol, acetic acid, pyridine, acetonitrile, acetone, tetrahydrofuran, or chloroform, or a mixture of two or more such organic solvents, and thereafter displacing the solvent with a displacing agent.

3. Paroxetine hydrochloride anhydrate Form A made according to the process of claim 1 in which the displacing agent is carbon dioxide.

4. Paroxetine hydrochloride anhydrate Form A made according to the process of claim 1 in which the displacing agent is water.

5. Paroxetine hydrochloride anhydrate Form A made according to the process of claim 2 which comprises crystallizing a paroxetine hydrochloride in propan-2-ol and thereafter displacing the solvent to less than 2% (w/w).

6. Paroxetine hydrochloride anhydrate of claim 5 wherein the the solvent is displaced to less than 1.8% (w/w).

7. Paroxetine hydrochloride anhydrate Form A made according to the process of claim 2 which comprises crystallizing a paroxetine hydrochloride in ethanol and thereafter displacing the solvent to less than 0.7% (w/w).

8. Paroxetine hydrochloride anhydrate Form A made according to the process of claim 2 which comprises crystallizing a paroxetine hydrochloride in acetone and thereafter displacing the solvent to less than 1.2% (w/w).

9. Paroxetine hydrochloride anhydrate Form A made according to the process of claim 2 which comprises crystallizing a paroxetine hydrochloride in tetrahydrofuran and thereafter displacing the solvent to less than 1.3% (w/w).

10. A process to prepare Paroxetine hydrochloride anhydrate Form A which process comprises crystallizing a paroxetine hydrochloride in an organic solvent or a mixture of organic solvents to prepare a paroxetine hydrochloride having organic solvent not removable by drying and thereafter displacing the solvent with a displacing agent, wherein paroxetine hydrochloride anhydrate Form A comprises the following characteristics: a melting point of about 123-125.degree. C.; IR bands at about 513, 538, 571, 592, 613, 665, 722, 761, 783, 806, 818, 839, 888, 906, 924, 947, 966, 982, 1006, 1034, 1068, 1091, 1134, 1194, 1221, 1248, 1286, 1340, 1387, 1493, 1513, 1562, 1604, 3402, and 3631 cm.sup.-1 ; a DSC maximum endotherm, measured at 10.degree. C. per minute, of about 126.degree. C. in an open pan and about 121.degree. C. in a closed pan; characteristic X-ray diffractogram peaks at about 6.6, 8.0, 11.2, and 13.1 degrees 2 theta; characteristic solid state .sup.13 C-NMR spectrum peaks at about 154.3, 149.3, 141.6, and 138.5 ppm.

11. The process of claim 10 which comprises crystallizing a paroxetine hydrochloride in propan-2-ol, propan-1-ol, ethanol, acetic acid, pyridine, acetonitrile, acetone, tetrahydrofuran, or chloroform, or a mixture of two or more such organic solvents, and thereafter displacing the solvent with a displacing agent.

12. The process of claim 10 in which the displacing agent is carbon dioxide.

13. The process of claim 10 in which the displacing agent is water.

14. The process of claim 11 which comprises crystallizing a paroxetine hydrochloride in propan-2-ol and thereafter displacing the solvent to less than 2% (w/w).

15. The process of claim 14 wherein the the solvent is displaced to less than 1.8% (w/w).

16. The process of claim 11 which comprises crystallizing a a paroxetine hydrochloride in ethanol and thereafter displacing the solvent to less than 0.7% (w/w).

17. The process of claim 11 which comprises crystallizing a paroxetine hydrochloride in acetone and thereafter displacing the solvent to less than 1.2% (w/w).

18. The process of claim 11 which comprises crystallizing a paroxetine hydrochloride in tetrahydrofuran and thereafter displacing the solvent to less than 1.3% (w/w).

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.